Researchers have come up with a diagnostic approach that they say could improve how autism is both identified and classified. The new technique, developed by a team at the Yeshiva University's Albert Einstein College of Medicine, joins a number of efforts with a goal of finding better ways to spot and treat the condition.
A long, rough patch in Fragile X syndrome drug R&D just got longer and rougher. Roche has notified patient groups that both of its mid-stage studies for RG7090--an mGluR5 therapy--failed to hit the primary and secondary goals, prompting the pharma giant to shut down the program.
Asuragen gained approval to start offering two of its key molecular diagnostic tests in New York state, milestones that will help boost the standard of care and give the Texas company another opportunity to grow its market reach.
Donald Trump has once again pushed a debunked link between vaccines and autism, this time weighing in after the Centers for Disease Control and Prevention published a report indicating that the number of children in America with the disorder has jumped from 1 in 88 two years ago to 1 in 68.
Low doses of a well-known class of drugs currently used in much higher doses to treat anxiety and epileptic seizures may be able to treat symptoms of autism, according to new research.
Andrew Wakefield was struck off the U.K. medical register and The Lancet retracted his paper that linked the MMR vaccine to autism, but the latest survey data suggests one in 5 Americans believe doctors know vaccines cause autism.
Startup SynapDx will team with the famed Broad Institute of Harvard and MIT to advance next-generation DNA sequencing for more accurate and clinically useful autism diagnostic tools.
Blogs and social media chatter often paint liberals, particularly Whole Foods-shopping, "earth mother" types, as the lead proponents of the anti-vaccine movement. Yet this view has been contradicted by surveys in the past, and was once again revealed to be flawed by data published this week.
A research team with the UC Davis MIND Institute believes an excess of cerebrospinal fluid and enlarged brain size in infancy could be two biomarkers for autism.
Seaside Therapeutics has revealed its second failed study for its lead drug STX209 this month. In one of two Phase III studies for the compound for the genetic mental disorder Fragile X syndrome, STX209 treatment missed its main goal of reducing social withdrawal.